Page 65 - CIBERES2016-ENG

0327-090000 “Vacuna Inactivada contra tuberculosis en base a una cepa modificada genéticamente”. 2013-16. Line 2: Polimorfismos genómicos y transcriptómicos en M. tuberculosis complex y su significado en clínica.
IP: Sofía Samper. Número de investigadores: 10; FIS 12/1970, Instituto de Salud Carlos III. Jan 2013-Jul 2016. • Análisis de las diferencias de IS6110 entre los miembros del complejo Mycobacterium tuberculosis y el papel de su localización en el origen de replicación. IP: Sofía Samper. Número de investigadores: 8; FIS 15/0317, Instituto de Salud Carlos III. 2016-18. • European Reference Laboratory Network for Tuberculosis (ERLTB-Net). Sofía Samper es miembro de la Red. 2014-17.
Line 3: MM4TBMore Medicines for Tuberculosis. European Union FP7. 2011-16 • NAREB - Nanotherapeutics for antibiotic resistant emerging bacterial pathogens. European Union FP7. 2014-18 • SAF-2013-48971-C2-2-R. Aplicaciones biomédicas de AS-48, una proteína con amplio espectro de actividad antimicrobiana. 2014-17
Most relevant scientific articles
• Aguilo N., Alvarez-Arguedas S., Uranga S., Marinova D., Monzon M., Badiola J. et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism. Journal of Infectious Diseases. 2016;212(11):831-839.
• Aguilo N., Uranga S., Marinova D., Monzon M., Badiola J., Martin C. MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis. 2016; 96:71-74.
• Molina-Moya B., Kazdaglis G., Lacoma A., Prat C., Gomez A., Villar-Hernandez R. et al. Evaluation of GenoFlow DR-MTB array test for detection of rifampin and isoniazid resistance in mycobacterium tuberculosis. Journal of Clinical Microbiology. 2016;54(4):1160-1163.
• Sagasti S., Millan-Lou M.I., Soledad Jimenez M., Martin C., Samper S. In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis. 2016; 100:46-52.
• Scriba T.J., Kaufmann S.H.E., Lambert P.H., Sanicas M., Martin C., Neyrolles O.. Vaccination against tuberculosis with whole-cell mycobacterial vaccines. Journal of Infectious Diseases. 2016;214(5):659-664.
Highlights
In 2016 we have continued our participation in the European TBVAC2020 project “Advancing novel and promising TB vaccine candidates for preclinical and early clinical development”, in collaboration with
40 universities and research centers. The solid safety data and immunogenicity of the first clinical trial in humans with MTBVAC in Phase 1a in adults in Lausanne Switzerland were critical in initiating the Phase 1b safety study in newborns in South Africa, an endemic country with one of the highest incidences of tuberculosis in the world. The vaccination phase of the babies ended in September 2016 (ClinicalTrials.gov Identifier: NCT02933281) and immunity results are expected by the end of 2017.
In the line of TRANSPOSITION and MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS project FIS 12/1970 was closed, and FIS 15/0317 started. The characteristics of the isolates of the most relevant tuberculosis complex in our environment and the different polymorphisms in their genomes were determined. The study of Beijing strains of Community Canaria was started. The genome of a M. bovis isolate XDR “B” has been published. We started with transcriptome studies. A “SNaPShot” pyrosequencing technique was performed and an ampliTaq faster and easier to perform technique which, in turn offers the molecular resistance profile of the isolate, and its phylogeny is being designed.
In the line of MOLECULAR BASIS OF DRUG RESISTANCE IN MYCOBACTERIA, during 2016 works on European project MM4TB have finalized, and positive results have been achieved in the analysis of the role of efflux in the activity of several new families of antituberculosis compounds. Based on previous works that resulted in the identification of a polymorphism specific of Beijing strains in a gene encoding an efflux pump, we have worked for simplifying the protocol for detection, which may facilitate its implementation in the clinic. Concerning other series of antituberculosis compounds, we have continued with its characterisation, in particular we have worked on drugs under development combined with nanoparticles.
RES
research groups 65